Asieris Pharmaceuticals Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 497

Employees

  • Stock Symbol
  • 688176

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.63
  • (As of Friday Closing)

Asieris Pharmaceuticals General Information

Description

Jiangsu Yahong Meditech Co Ltd is engaged in the field of urogenital system tumors and other diseases.

Contact Information

Website
www.asieris.cn
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 8F Building 56
  • 1000 Jinhai Rd. Pudong
  • Shanghai, 201206
  • China
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
SHG
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 8F Building 56
  • 1000 Jinhai Rd. Pudong
  • Shanghai, 201206
  • China

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Asieris Pharmaceuticals Stock Performance

As of 13-Nov-2026, Asieris Pharmaceuticals’s stock price is $1.63. Its current market cap is $933M with 572M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.63 $1.68 $1.31 - $2.62 $933M 572M 12.8M -$0.14

Asieris Pharmaceuticals Financials Summary

As of 30-Sep-2026, Asieris Pharmaceuticals has a trailing 12-month revenue of $46.4M.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,118,855 742,820 340,374 542,513
Revenue 46,378 38,536 28,091 1,944
EBITDA (78,502) (55,221) (52,042) (59,575)
Net Income (76,774) (57,900) (53,525) (56,599)
Total Assets 267,475 294,066 304,515 371,339
Total Debt 58,587 49,330 18,154 18,968
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Asieris Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Asieris Pharmaceuticals‘s full profile, request access.

Request a free trial

Asieris Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Jiangsu Yahong Meditech Co Ltd is engaged in the field of urogenital system tumors and other diseases.
Drug Discovery
Shanghai, China
497 As of 2025

Beijing, China
 

Shanghai, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Asieris Pharmaceuticals Competitors (5)

One of Asieris Pharmaceuticals’s 5 competitors is CANbridge Pharma, a Formerly VC-backed company based in Beijing, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CANbridge Pharma Formerly VC-backed Beijing, China
JW Therapeutics Formerly VC-backed Shanghai, China
Harbour BioMed Formerly VC-backed Shanghai, China
Adagene Formerly VC-backed Suzhou, China
NeoX Biotech Venture Capital-Backed Beijing, China
You’re viewing 5 of 5 competitors. Get the full list »

Asieris Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Asieris Pharmaceuticals Investments (2)

Asieris Pharmaceuticals’s most recent deal was a Early Stage VC with Hangzhou Bailit Biopharmaceuticals. The deal was made on 17-Feb-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Hangzhou Bailit Biopharmaceuticals 17-Feb-2025 Early Stage VC Biotechnology
Uroviu 27-Jul-2017 Early Stage VC Diagnostic Equipment
To view Asieris Pharmaceuticals’s complete investments history, request access »

Asieris Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Asieris Pharmaceuticals’s complete esg history, request access »

Asieris Pharmaceuticals FAQs

  • When was Asieris Pharmaceuticals founded?

    Asieris Pharmaceuticals was founded in 2010.

  • Where is Asieris Pharmaceuticals headquartered?

    Asieris Pharmaceuticals is headquartered in Shanghai, China.

  • What is the size of Asieris Pharmaceuticals?

    Asieris Pharmaceuticals has 497 total employees.

  • What industry is Asieris Pharmaceuticals in?

    Asieris Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Asieris Pharmaceuticals a private or public company?

    Asieris Pharmaceuticals is a Public company.

  • What is Asieris Pharmaceuticals’s stock symbol?

    The ticker symbol for Asieris Pharmaceuticals is 688176.

  • What is the current stock price of Asieris Pharmaceuticals?

    As of 13-Nov-2026 the stock price of Asieris Pharmaceuticals is $1.63.

  • What is the current market cap of Asieris Pharmaceuticals?

    The current market capitalization of Asieris Pharmaceuticals is $933M.

  • What is Asieris Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Asieris Pharmaceuticals is $46.4M.

  • Who are Asieris Pharmaceuticals’s competitors?

    CANbridge Pharma, JW Therapeutics, Harbour BioMed, Adagene, and NeoX Biotech are competitors of Asieris Pharmaceuticals.

  • What is Asieris Pharmaceuticals’s annual earnings per share (EPS)?

    Asieris Pharmaceuticals’s EPS for 12 months was -$0.14.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process